Glenmark Pharmaceuticals Inc., USA, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited, has announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial in the United States. The newly launched product is bioequivalent and therapeutically equivalent to Zyprexa® IntraMuscular Injection 10 mg/vial (NDA 021253) marketed by Cheplapharm Registration GmbH.
The launch further strengthens Glenmark's presence in the institutional injectable medicines segment and supports the company's strategy of expanding its portfolio of high-quality, affordable hospital-based therapies.
According to IQVIA National Sales Perspectives data for the 12-month period ending May 2026, the U.S. market for Zyprexa® IntraMuscular Injection, including all therapeutic equivalents, recorded annual sales of approximately US$25.4 million.
Commenting on the development, Marc Kikuchi, President & Business Head, North America, Glenmark Pharmaceuticals Inc., USA, said:
"The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers."
Glenmark stated that its Olanzapine for Injection has been approved only for the indications specified in the company's approved U.S. product label.
Glenmark Pharmaceuticals Limited is a global, research-led pharmaceutical company with operations in more than 80 countries. The company operates 11 manufacturing facilities across four continents and six research and development centres, offering a diversified portfolio of branded medicines, generics, innovative therapies, and consumer healthcare products. Its key therapeutic focus areas include respiratory diseases, dermatology, and oncology.
